<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88916">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01747252</url>
  </required_header>
  <id_info>
    <org_study_id>08/12</org_study_id>
    <nct_id>NCT01747252</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Resveratrol Comprising Products</brief_title>
  <official_title>Randomized Three-way Cross-over Comparative Pharmacokinetic Study of Resveratrol Comprising Products in Fasting Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fruitura Bioscience Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fruitura Bioscience Ltd.</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to assess the pharmacokinetics of 2 doses of Red Grape Cells (RGC)
      containing resveratrol compared with a reference. RGC will be administered as single oral
      dose to fasting healthy volunteers. Plasma concentration of free resveratrol and total
      conjugates will be analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Individual plasma concentrations of free and conjugated resveratrol</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic data such as the peak plasma concentration (Cmax), time to peak (Tmax) ans area under the concentration-time curves (AUCt) will be reported.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>RGC1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGC containing the equivalent of 50 mg resveratrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The equivalent of 150 mg resveratrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGC2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGC containing the equivalent of 150 mg resveratrol</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>RGC</intervention_name>
    <arm_group_label>RGC1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>RGC</intervention_name>
    <arm_group_label>RGC2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>The equivalent of 150 mg resveratrol</description>
    <arm_group_label>Resveratrol</arm_group_label>
    <other_name>Transmax (Biotivia Ltd.)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-55 years;

          -  BMI &gt;/= 19 and &lt;/= 30

          -  non smoking

          -  without history or evidence of significant cardiovascular, hepatic, renal,
             respiratory, gastrointestinal disease

          -  normal physical and laboratory examinations

        Exclusion Criteria:

          -  History or evidence of alcohol or drug abuse

          -  subjects receiving chronic medication

          -  unusual dietary habits or a recent change in body weight

          -  acute medical situation 48 hours prior to initiation of the study

          -  poor venous access

          -  Subjects participated in a trial or donated blood within 4 weeks before initiation of
             the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BioStudies Center</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 1, 2013</lastchanged_date>
  <firstreceived_date>December 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
